Epidemiology and Risk Factors in Non-infectious Uveitis: A Systematic Review

Joltikov, Katherine A.; Lobo-Chan, Ann-Marie

doi:10.3389/fmed.2021.695904

Cited by 50 publications

(31 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Uveitis is an important clinical problem, with high prevalence worldwide, 34 and with high visual morbidity. 35 It is an umbrella term for a range of clinical entities, and the range of different aetiologies for uveitis, including infectious, autoimmune and autoinflammatory, traumatic and ischaemic causes, means that single overarching guidelines are difficult to produce.…”

Section: Discussionmentioning

confidence: 99%

Systematic review of clinical practice guidelines for uveitis

et al. 2023

View full text Add to dashboard Cite

To facilitate the integration of eye care into universal health coverage, the WHO is developing a Package of Eye Care Interventions (PECI). Development of the PECI involves the identification of evidence-based interventions from relevant clinical practice guidelines (CPGs) for uveitis.A systematic review of CPGs published on uveitis between 2010 and March 2020 was conducted. CPGs passing title and abstract and full-text screening were evaluated using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool and data on recommended interventions extracted using a standard data extraction sheet.Of 56 CPGs identified as potentially relevant from the systematic literature search, 3 CPGs underwent data extraction following the screening stages and appraisal with the AGREE II tool. These CPGs covered screening for, monitoring and treating juvenile idiopathic arthritis (JIA)-associated uveitis, the use of adalimumab and dexamethasone in treating non-infectious uveitis, and a top-level summary of assessment, differential diagnosis and referral recommendations for uveitis, aimed at primary care practitioners. Many of the recommendations were based on expert opinion, though some incorporated clinical study and randomised controlled trial data.There is currently sparse coverage of the spectrum of disease caused by uveitis within CPGs. This may partially be due to the large number of conditions with diverse causes and clinical presentations covered by the umbrella term uveitis, which makes numerous sets of guidelines necessary. The limited pool of CPGs to select from has implications for clinicians seeking guidance on clinical care strategies for uveitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Systematic review of clinical practice guidelines for uveitis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In some cases, the submitted reports are incomplete, and lack uniformity in data reporting, and several reports have missing data points such as ethnicity, which are considered important risk factors associated with uveitis. 44 , 45 , 46 , 47 The VAERS data is broadly stratified into uveitis (uncategorized), autoimmune uveitis, Behcet’s syndrome, chorioretinitis, choroiditis, herpes ophthalmicus, intermediate uveitis, iridocyclitis, keratouveitis, tubulointerstitial nephritis and uveitis syndrome, and uveitis-glaucoma-hyphaema syndrome on the basis of MedDRA definitions, limiting the insight into the clinical diagnosis in these patients. The data reported in this study only suggest a temporal relationship between uveitis onset and SARS-CoV-2 vaccination and does not demonstrate a causal relationship and further investigations are required to establish a causal relationship.…”

Section: Limitationsmentioning

confidence: 99%

Vaccine-Associated Uveitis after COVID-19 Vaccination

Singh¹,

Parmar²,

Kahale³

et al. 2023

Ophthalmology

View full text Add to dashboard Cite

“…1,2 Unlike other ocular diseases, uveitis may occur at any age, although it most commonly affects adults of working-age, 1,3 with the ensuing social and economic impact. [4][5][6] The estimated average annual incidence of uveitis is 50.45 per 100,000, 1,7,8 with a geographic variation in prevalence from 9 to 730 cases per 100,000 individuals. 9 The main causes of the visual loss associated with uveitis are cystoid macular edema (CME), 3,4,10 which can provoke structural changes in the retina and cataracts, and complications associated with increased intraocular pressure (IOP).…”

Section: Introductionmentioning

confidence: 99%

“…The majority of uveitis cases (67-90%) are non-infectious, 7,[11][12][13] making this the third-leading cause of preventable blindness worldwide. 14 Uveitis is classified into anterior, intermediate and posterior according to the part of the uvea that is affected.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Non-Infectious Posterior Uveitis with Dexamethasone Intravitreal Implants in a Real-World Setting

Butt¹,

Devonport²

2023

OPTH

View full text Add to dashboard Cite

The present study aimed to assess the efficacy and safety associated to the treatment of patients with non-infectious posterior uveitis with intravitreal dexamethasone (DEX) implants in a real-world clinical setting. Patients and Methods: This is a retrospective, single center analysis of the data from 29 patients with non-infectious posterior uveitis in whom 38 eyes were treated with dexamethasone intravitreal implants in routine clinical practice between January 2012 and October 2017. The parameters of visual acuity (VA), intraocular pressure (IOP) and central retinal thickness (CRT) were recorded 6 weeks after the first implant was administered, in accordance with the clinical guidelines for the use of these implants, and after a 6-month follow-up period. In addition, the formation of cataracts was evaluated at 12 months. Results: Treatment with the DEX implant caused a significant improvement in the VA from baseline at 6 weeks in eyes treated with 2-6 implants and for eyes without cataracts. A significant decrease in CRT was observed relative to the baseline at 6 weeks for eyes treated with 1 and 2-6 implants, which was maintained at 6 months for those eyes treated with 2-6 implants. This significant improvement in CRT at 6 weeks and 6 months was evident in eyes with and without cataracts. During the study period, the IOP was found to increase significantly from baseline at 6 weeks in some eyes but this was managed topically, and no surgical intervention was necessary. Conclusion: Intravitreal DEX implants represent an effective and safe therapy for the treatment of non-infectious uveitis in routine clinical practice, producing favorable visual and anatomical outcomes after the administration of just 2-6 DEX implants.

show abstract

Epidemiology and Risk Factors in Non-infectious Uveitis: A Systematic Review

Cited by 50 publications

References 82 publications

Systematic review of clinical practice guidelines for uveitis

Systematic review of clinical practice guidelines for uveitis

Vaccine-Associated Uveitis after COVID-19 Vaccination

Treatment of Non-Infectious Posterior Uveitis with Dexamethasone Intravitreal Implants in a Real-World Setting

Contact Info

Product

Resources

About